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Dear Editor,
We read with great interest a recent article by Dorababu et
al. titled “Epistatic interactions between thiopurine methyl-
transferase (TPMT) and inosine triphosphate pyrophospha-
tase (ITPA) variations determine the 6-mercaptopurine
toxicity in Indian children with acute lymphoblastic leuke-
mia (ALL)” published in your journal [1]. It is interesting
that the authors described the combined influence of TPMT
and ITPA genetic variants on 6-mercaptopurine-induced
toxicity using multidimensional reduction analysis. We
therefore have a few comments on the following aspects of
the article. It is known that TPMT activity is influenced by
age and sex in children. Higher activity was observed in
male children compared with female children and adults of
normal genotype [2]. Age and sex must be considered in
evaluating TPMT activity or its adverse effects. The authors
adjusted for age and body surface area in multivariate analy-
sis, but sex was not adjusted for. As the study population
comprised children of both genders, the investigators might
have analyzed age and sex differences in toxicity among
different TPMT genotypes. The authors used multiple linear
regression analysis to predict hematological toxicity and
found that 27% of the variability in toxicity could be deter-
mined by the genotypes of TPMT and ITPA. However, the
contribution of age, sex, or other demographic characteristics
toward toxicity was ignored. The distribution of age and sex,
details of ALL types (T or B), relapse status, and risk stratifi-
cation was not mentioned under different genotype categories
in patients receiving MCP-841 protocol. [3]. The reader
would be interested to know the impact of genotype on
toxicity in specific ALL types.
As the authors of the article sequenced the entire TPMT
gene, they might consider constructing TPMT haplotypes
and correlate them with toxicity. This will give an idea about
the influence of all variants together. Instead, the authors
checked for correlation of genetic variants individually with
that of hematological toxicity yielding low coefficients
(0.28, 0.3) [4, 5]. Similarly, ITPA haplotypes and the inter-
action of both haplotypes with toxicity may be investigated.
It seems that the population has unique haplotypes, and the
authors must refer to the report by Jones et al. for haplotype
information on TPMT [6]. Some genetic variants are not in
Hardy–Weinberg equilibrium. This indicates error in geno-
typing or that samples are from one cluster (mentioned in
the discussion section) or might have been associated with
clinical parameters or the disease. The authors might inves-
tigate this aspect thoroughly so as not to miss any important
findings. Further studies in this area must also consider
points suggested by us and by the authors.
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